Specifically, we propose CX-5461 will have efficacy in HR-deficient HGSOC and in HGSOC tumours with elevated MYC activity such as the high-MYCN HGSOC subtype associated with poor prognosis26,44. The gene discussed is MYCN; the disease is neoplasm.